Related Experiment Video
Updated: Aug 9, 2026
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Experimental local therapy of human melanoma with lytic magainin peptides
P W Soballe1, W L Maloy, M L Myrga
1Wistar Institute, Philadelphia, PA 19104.
Abstract:
Magainin peptides and model amphipathic peptides exhibit antibiotic activity and are also cytolytic for transformed human cells. Here we demonstrate in vitro that MSI-511 (an all-D amino-acid model magainin peptide) and MSI-130 (a margainin analogue) were more lytic for 17 human melanomas than for normal melanocytes. Melanomas established s.c. in athymic nude mice and then injected once with the peptide MSI-511 completely disappeared in 6 out of 9 animals, whereas a control peptide had no effect. Murine skin at the tumor injection site was initially affected, but healed within 2 weeks with minimal scarring. Similarly, accelerated healing was seen in human skin grafted to SCID mice and injected with MSI-511. Our results indicate that lytic magainin peptides can be used for local tumor therapy with minimal long-term damage to normal tissues.
Insights
Lytic magainin peptides, like MSI-511, show promise for melanoma treatment. These peptides selectively target cancer cells, leading to tumor disappearance in mice with minimal damage to surrounding tissues.
Area of Science:
- Biochemistry
- Oncology
- Dermatology
Background:
- Magainin peptides and model amphipathic peptides possess antibiotic and cytolytic properties.
- These peptides demonstrate selective toxicity towards transformed human cells.
Purpose of the Study:
- To evaluate the efficacy of lytic magainin peptides, specifically MSI-511 and MSI-130, in targeting and treating human melanomas.
- To assess the therapeutic potential of MSI-511 for local tumor therapy with minimal damage to normal tissues.
Main Methods:
- In vitro analysis of peptide lytic activity against human melanoma cell lines and normal melanocytes.
- In vivo studies using athymic nude mice with established subcutaneous melanomas, treated with MSI-511.
- Assessment of tissue healing and scarring at the injection site in both murine and human skin grafts.
Main Results:
- MSI-511 and MSI-130 exhibited greater lytic activity against 17 human melanoma cell lines compared to normal melanocytes.
- Complete melanoma tumor regression was observed in 6 out of 9 mice treated with a single injection of MSI-511.
- Initial transient skin effects at the tumor injection site healed within 2 weeks with minimal scarring; accelerated healing was noted in human skin grafts.
Conclusions:
- Lytic magainin peptides demonstrate selective cytotoxicity towards melanoma cells, offering a potential therapeutic strategy.
- MSI-511 can effectively induce complete tumor regression in a preclinical model of melanoma.
- These findings suggest that lytic magainin peptides are a viable option for local tumor therapy with a favorable safety profile for normal tissues.
More Related Videos
08:18Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
